First pilot study of NGC 0295 (NsG0202) in patients with Alzheimer's disease
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2010
At a glance
- Drugs NGC 0295 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors NsGene
- 04 Nov 2008 NsG 0202 has successfully been implanted in six patients and in patients have been enrolled, according to a NsGene media release.
- 13 May 2008 New trial record.